Mirae Asset Global ETFs Holdings’s BridgeBio Oncology BBOT Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.1K	Buy	+2,626	New	+$21.9K	﹤0.01%	3116

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's BBOT Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings opened a new position in BridgeBio Oncology (BBOT) in Q2 2026: 2,626 shares worth $20.1K. The stake represents ﹤0.01% of the portfolio and ranks #3116 among its holdings.

66 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

Mirae Asset Global ETFs Holdings held 2,626 shares of BridgeBio Oncology worth $20.1K as of Q2 2026.
BridgeBio Oncology was a new Mirae Asset Global ETFs Holdings position in Q2 2026.
BridgeBio Oncology made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #3116 holding.
66 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.